TrialThe oncologist2022

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.

Yasuyuki Kawamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.